Table 1

Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on aluminium adjuvants

GACVS reportExposureOutcomeReport link
1999SeptemberAluminiumMMFhttps://www.who.int/vaccine_safety/committee/reports/wer7441.pdf?ua=1
2002JuneAluminiumMMFhttps://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1
2003DecemberAluminiumMMFhttps://www.who.int/vaccine_safety/committee/reports/wer7903.pdf?ua=1
2004JuneAdjuvants (general)General safetyhttps://www.who.int/vaccine_safety/committee/reports/wer7929.pdf?ua=1
2004DecemberAdjuvants (general)General safetyhttps://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8001.pdf?ua=1
2005DecemberAdjuvants (general)General safetyhttps://www.who.int/vaccine_safety/committee/reports/wer8102.pdf?ua=1
2012JuneAluminiumAutismhttps://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1
AluminiumPharmaco-kinetics

  • MMF, macrocytic myofasciitis.